Jason Pesile
Director of Finance/CFO presso VAXXINITY, INC.
Patrimonio netto: - $ in data 31/03/2024
Profilo
Jason Pesile is currently the Senior Vice President-Finance & Accounting at Vaxxinity, Inc. He previously worked as a Director at Merck & Co., Inc. from 2009 to 2011.
He also held the position of Director at Schering-Plough Corp.
In addition, he served as the Executive Director-Finance at Progenics Pharmaceuticals, Inc. from 2016 to 2020.
He was also the Vice President-Finance at electroCore, Inc. Furthermore, he worked as the Vice President-Finance & Controller at BeyondSpring Pharmaceuticals, Inc. from 2020 to 2021.
Mr. Pesile obtained his undergraduate degree from The Wharton School of the University of Pennsylvania and holds an MBA from Columbia Business School.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
VAXXINITY INC CLASS A
-.--% | 07/03/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Jason Pesile
Società | Posizione | Inizio |
---|---|---|
VAXXINITY, INC. | Director of Finance/CFO | 03/01/2022 |
Precedenti posizioni note di Jason Pesile
Società | Posizione | Fine |
---|---|---|
BeyondSpring Pharmaceuticals, Inc.
BeyondSpring Pharmaceuticals, Inc. BiotechnologyHealth Technology Part of BeyondSpring, Inc., BeyondSpring Pharmaceuticals, Inc. is a clinical-stage bio-pharmaceutical company that develops innovative immuno-oncology cancer therapies. The private company is based in New York, NY. The company has a robust pipeline from internal development and collaboration with the University of Washington in de novo drug discovery using a ubiquitination platform. The CEO of the company is Lan Huang. | Comptroller/Controller/Auditor | 01/01/2021 |
PROGENICS PHARMACEUTICALS, INC. | Director of Finance/CFO | 01/07/2020 |
ELECTROCORE, INC. | Director of Finance/CFO | 06/06/2015 |
MERCK & CO., INC. | Corporate Officer/Principal | 01/07/2011 |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Director/Board Member | - |
Formazione di Jason Pesile
The Wharton School of the University of Pennsylvania | Undergraduate Degree |
Columbia Business School | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
MERCK & CO., INC. | Health Technology |
ELECTROCORE, INC. | Health Technology |
VAXXINITY, INC. | Health Technology |
Aziende private | 3 |
---|---|
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
Progenics Pharmaceuticals, Inc.
Progenics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon on December 1, 1986 and is headquartered in New York, NY. | Health Technology |
BeyondSpring Pharmaceuticals, Inc.
BeyondSpring Pharmaceuticals, Inc. BiotechnologyHealth Technology Part of BeyondSpring, Inc., BeyondSpring Pharmaceuticals, Inc. is a clinical-stage bio-pharmaceutical company that develops innovative immuno-oncology cancer therapies. The private company is based in New York, NY. The company has a robust pipeline from internal development and collaboration with the University of Washington in de novo drug discovery using a ubiquitination platform. The CEO of the company is Lan Huang. | Health Technology |
- Borsa valori
- Insiders
- Jason Pesile